Stock ATNM ACTINIUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Actinium Pharmaceuticals, Inc.

Equities

ATNM

US00507W2061

Real-time Estimate Cboe BZX
Other stock markets
 02:06:15 2024-04-29 pm EDT 		5-day change 1st Jan Change
7.355 USD +7.06% Intraday chart for Actinium Pharmaceuticals, Inc. +2.79% +45.08%
Apr. 26 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 18 Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Maxim Adjusts Actinium Pharmaceuticals' Price Target to $30 From $20, Maintains Buy Rating
MT
B. Riley Adjusts Price Target on Actinium Pharmaceuticals to $16 From $20, Maintains Buy Rating
MT
HSBC Starts Actinium Pharmaceuticals With Buy Rating, Price Target is $11.60
MT
HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $50 From $53, Keeps Buy Rating
MT
B. Riley Raises Actinium Pharmaceuticals' Price Target to $20 From $18, Keeps Buy Rating
MT
William Blair Downgrades Actinium Pharmaceuticals to Market Perform Rating From Outperform
MT
HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $53 From $45, Maintains Buy Rating
MT
B. Riley Raises Actinium Pharmaceuticals' PT to $18 From $16 After Positive Update of Phase 3 SIERRA Trial for Iomab-B, Keeps Buy Rating
MT
Cantor Fitzgerald Initiates Actinium Pharmaceuticals at Overweight with $20 Price Target
MT
B. Riley Securities Initiates Actinium Pharmaceuticals at Buy with $16 Price Target, Says Market Potential for Iomab-B Conditioning Underappreciated
MT
Alliance Global Adjusts Price Target on Actinium Pharmaceuticals to $25 From $20, Maintains Buy Rating
MT
Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML
CI
ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Actinium Pharmaceuticals' Price Target to $45 From $57, Maintains Buy Rating
MT
ACTINIUM PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Actinium Pharmaceuticals to $57 From $65, Maintains Buy Rating
MT
Actinium Pharmaceuticals, Inc. Reports 67% Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH
CI
ACTINIUM PHARMACEUTICALS : Alliance Global Starts Actinium Pharmaceuticals at Buy With $25 Price Target
MT
Actinium Pharmaceuticals : Reports 100% Remission Rate in Cohort of Phase 1 Study of Actimab-A CLAG; Shares Rise 10%
MT
Actinium Pharmaceuticals, Inc. Announces 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML
CI
Actinium Pharmaceuticals, Inc. Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ATNM Stock
  4. News Actinium Pharmaceuticals, Inc.
  5. Analyst Reco.